Open AccessTicagrelor in patients with stable coronary artery disease: a role in improving prognosis
Author(s) -
Tatia. Novikova
Publication year - 2020
Publication title -
rossijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 14
eISSN - 2618-7620
pISSN - 1560-4071
DOI - 10.15829/1560-4071-2020-4094
Subject(s) - medicine , ticagrelor , coronary artery disease , antithrombotic , cardiology , adverse effect , randomized controlled trial , artery , clinical trial , aspirin , clopidogrel
The aim of this review was to study the evidence base for the efficacy and safety of the P2Y 12 receptor blocker ticagrelor in combination with acetylsalicylic acid in patients with stable coronary artery disease and high and moderate risk of adverse cardiovascular events. Currently, the mortality rate of this category of patients remains high. Long-term dual antithrombotic therapy allows to improve the prognosis. Ticagrelor at a low dose (60 mg 2 times a day) in combination with acetylsalicylic acid in randomized clinical trials and an actual clinical practice has shown a beneficial effect on prognosis in stable coronary artery disease.